OBJECTIVE: To identify factors at the health facility and health professional levels that might hinder or facilitate the appropriate use of magnesium sulfate for the treatment of pre-eclampsia and eclampsia. METHODS: Seven focus group discussions were conducted with a purposively sampled group of obstetricians/gynecologists, medical residents, and nurses at 3 hospitals in Nagpur, India. Data were collected on facility and drug availability, criteria for diagnosis and management of pre-eclampsia and eclampsia, attitudes about magnesium sulfate use, and perceived barriers to the treatment of pre-eclampsia and eclampsia. RESULTS: Senior gynecologists seemed to encourage the use of magnesium sulfate, especially management prior to transfer to a higher facility. However, clinicians noted a lack of specific institutional guidelines on dose, timing, and indications, particularly in cases in which delivery was not imminent. In all facilities, service providers noted that their clinical care decisions were sometimes influenced by political and social factors, making management of eclampsia and pre-eclampsia cases difficult. Care was further challenged by limited drug availability, particularly at the tertiary-care center. CONCLUSION: Limited drug supply and lack of specific institutional guidelines, equipment, and trained staff hinder the translation of evidence-based policy on magnesium sulfate into practice.
OBJECTIVE: To identify factors at the health facility and health professional levels that might hinder or facilitate the appropriate use of magnesium sulfate for the treatment of pre-eclampsia and eclampsia. METHODS: Seven focus group discussions were conducted with a purposively sampled group of obstetricians/gynecologists, medical residents, and nurses at 3 hospitals in Nagpur, India. Data were collected on facility and drug availability, criteria for diagnosis and management of pre-eclampsia and eclampsia, attitudes about magnesium sulfate use, and perceived barriers to the treatment of pre-eclampsia and eclampsia. RESULTS: Senior gynecologists seemed to encourage the use of magnesium sulfate, especially management prior to transfer to a higher facility. However, clinicians noted a lack of specific institutional guidelines on dose, timing, and indications, particularly in cases in which delivery was not imminent. In all facilities, service providers noted that their clinical care decisions were sometimes influenced by political and social factors, making management of eclampsia and pre-eclampsia cases difficult. Care was further challenged by limited drug availability, particularly at the tertiary-care center. CONCLUSION: Limited drug supply and lack of specific institutional guidelines, equipment, and trained staff hinder the translation of evidence-based policy on magnesium sulfate into practice.
Authors: Q Long; O T Oladapo; S Leathersich; J P Vogel; G Carroli; P Lumbiganon; Z Qureshi; A M Gülmezoglu Journal: BJOG Date: 2016-11-24 Impact factor: 6.531
Authors: Maria Chifuniro Chikalipo; Lester Kapanda Phiri; Neggie Mndolo; Christina Ruth Mbiza; Patricia Khisi; Eunice Golombe; Phylos Bonongwe; Ellen Mbweza Chirwa; Alfred Maluwa Journal: Int J Womens Health Date: 2020-03-18
Authors: Zenewton André da Silva Gama; Wilton Rodrigues Medeiros; Pedro Jesus Saturno-Hernández; Kelienny de Meneses Sousa; Matheus Silva Mello; Érico de Lima Vale; Tatyana Maria Silva de Souza Rosendo; Edna Marta Mendes da Silva; Marise Reis de Freitas Journal: BMC Pregnancy Childbirth Date: 2020-03-12 Impact factor: 3.007
Authors: Jeffrey Michael Smith; Richard F Lowe; Judith Fullerton; Sheena M Currie; Laura Harris; Erica Felker-Kantor Journal: BMC Pregnancy Childbirth Date: 2013-02-05 Impact factor: 3.007